First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study

SIMPLE SUMMARY: Chemoimmunotherapy (CIT) improved overall survival and progression-free survival (PFS) among patients with non-small cell lung cancer (NSCLC), while CIT showed limited efficacy among the subgroup with ≤49% programmed death-ligand 1 (PD-L1) expression. Therefore, sequential treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanimura, Keiko, Takeda, Takayuki, Kataoka, Nobutaka, Yoshimura, Akihiro, Nakanishi, Kentaro, Yamanaka, Yuta, Yoshioka, Hiroshige, Honda, Ryoichi, Uryu, Kiyoaki, Fukui, Mototaka, Chihara, Yusuke, Takei, Shota, Kawachi, Hayato, Yamada, Tadaaki, Tamiya, Nobuyo, Okura, Naoko, Yamada, Takahiro, Murai, Junji, Shiotsu, Shinsuke, Kurata, Takayasu, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605814/
https://www.ncbi.nlm.nih.gov/pubmed/37894357
http://dx.doi.org/10.3390/cancers15204988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605814/
https://www.ncbi.nlm.nih.gov/pubmed/37894357
http://dx.doi.org/10.3390/cancers15204988

Ejemplares similares